$ABCL News

AbCellera to Present at Upcoming Investor Conferences in November 2026

UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18

AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws Focus

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17

Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

AbCellera To Present Phase 2 Data On ABCL635 At IMS 20th World Congress On Menopause

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

AbCellera (ABCL) Q2 2026 Earnings Call Transcript

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?

AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading

AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common Shares

AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 Data